LAG3 and neoplasm: The expression of LAG-3in at least 1% (n = 25) of tumor-associated immune cells within the tumor margin was associated with an almost triple improvement in ORRs compared to patients without LAG-3 expression (n = 14) (20% and 7.1%, respectively) [54].